Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014187654) POLYMER DRUG CONJUGATES FOR THE TREATMENT OF AMYLOIDOSIS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/187654 International Application No.: PCT/EP2014/058856
Publication Date: 27.11.2014 International Filing Date: 30.04.2014
Chapter 2 Demand Filed: 17.03.2015
IPC:
A61K 47/48 (2006.01) ,A61K 49/00 (2006.01) ,A61K 49/14 (2006.01) ,A61K 51/08 (2006.01) ,A61P 25/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
48
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49
Preparations for testing in vivo
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49
Preparations for testing in vivo
06
Nuclear magnetic resonance (NMR) contrast preparations; Magnetic resonance imaging (MRI) contrast preparations
08
characterised by the carrier
10
Organic compounds
14
Peptides, e.g. proteins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51
Preparations containing radioactive substances for use in therapy or testing in vivo
02
characterised by the carrier
04
Organic compounds
08
Peptides, e.g. proteins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
28
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants:
FUNDACION DE LA COMUNIDAD VALENCIANA "CENTRO DE INVESTIGACIONES PRINCIPE FELIPE" [ES/ES]; Avda. Eduardo Primo Yúfera, 3 E-46012 Valencia, ES
Inventors:
VICENT DOCÓN, María Jesús; ES
CONEJOS SANCHEZ, Inmaculada; ES
Agent:
DE CARLOS HERNANDO, Borja; Garrigues IP, S.L.P Hermosilla, 3 E-28001 Madrid, ES
Priority Data:
13382184.320.05.2013EP
Title (EN) POLYMER DRUG CONJUGATES FOR THE TREATMENT OF AMYLOIDOSIS
(FR) CONJUGUES DE MEDICAMENTS POLYMERES POUR LE TRAITEMENT DE L'AMYLOSE
Abstract:
(EN) The present invention is referred to novel polymeric conjugates to which at least it is linked a fibril disruptor agent and/or a aggregates blocking agent, and additionally a targeting moiety and/or a probe for therapy and diagnosis. In the polymer-drug conjugate, the polymeric platform transports at least one bioactive agent, selected from the group of anthracyclines antibiotics which includes tetracycline, rolitethracycline, minocycline and/or doxycycline and their derivatives, etc..., able to disaggregate or break the amyloid fibrils and/or block the aggregates. This conjugate could contain in its structure one or several targeting moieties, which will provide an effective targeting of the polymer-drug conjugate to the selected diseased area for drug activity, increasing the therapeutic efficacy in the treatment of amyloidosis related diseases, including amyloidosis related to polyneuropathic disorders and neurodegenerative diseases like FAP and AD.
(FR) La présente invention concerne de nouveaux conjugués polymères auxquels sont reliés au moins un agent perturbateur de fibrille et/ou un agent de blocage d'agrégat, et, en outre, une fraction de ciblage et/ou une sonde pour une thérapie et un diagnostic. Dans le conjugué de médicaments polymères, la plateforme polymère transporte au moins un agent bioactif, sélectionné dans le groupe d'antibiotiques d'anthracycline qui comprend de la tétracycline, de la rolitétracycline, de la minocycline et/ou de la doxycycline et leurs dérivés, etc..., aptes à désagréger ou à rompre les fibrilles amyloïdes et/ou à bloquer les agrégats. Le conjugué de la présente invention peut contenir dans sa structure une ou plusieurs fractions de ciblage, qui fourniront un ciblage efficace du conjugué de médicaments polymères à la région malade sélectionnée pour une activité de médicament, augmentant l'efficacité thérapeutique du traitement de maladies liées à l'amylose, comprenant l'amylose associée à des troubles polyneuropathiques et à des maladies neurodégénératives, telles que FAP et AD.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)